by Team Small News | Sep 28, 2025 | Glenmark, Pharma, Sun Pharma, Zydus
Several Indian pharmaceutical companies are recalling medicines from the US market due to various issues, as reported by the US Food and Drug Administration (USFDA). The recalls are related to manufacturing problems, impurities, and labeling errors. Glenmark...
by Team Small News | Sep 28, 2025 | Glenmark, Pharma, Sun Pharma, Zydus
Several Indian pharmaceutical companies are recalling medicines from the US market due to various issues, including manufacturing problems, impurities, and labeling errors, as reported by the US Food and Drug Administration (USFDA). The recalls affect a range of... by Team Small News | Sep 27, 2025 | Glenmark, Pharma
Fierce Pharma Asia recently reported on several key developments in the pharmaceutical industry. One major story is Celltrion’s acquisition of a Lilly manufacturing plant in China. This move is expected to enhance Celltrion’s presence in the Chinese market... by Team Small News | Sep 19, 2025 | Glenmark, Pharma
Crisil Ratings has revised the outlook on Glenmark Pharmaceuticals Limited’s long-term bank facilities to ‘Positive’ from ‘Stable’, while reaffirming the rating at ‘Crisil AA’. The short-term rating remains at ‘Crisil...
by Team Small News | Sep 14, 2025 | Aurobindo Pharma, Biocon, Cipla, Glenmark, Lupin, Mankind, Pharma, Sun Pharma, Torrent Pharma, Zydus
The pharmaceutical industry is complex, with various segments such as innovator products, generics, branded generics, and API. Indian companies are making headway globally, and understanding the industry’s intricacies is crucial for those seeking opportunities.... by Team Small News | Sep 3, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5...